Dr. Hans Lee on MRNA-2808 in relapsed or refractory multiple myeloma

Hans Lee, MD, director of Myeloma Research at the Sarah Cannon Research Institute, discusses an early phase 1/2 clinical trial evaluating the investigational therapy mRNA-2808 in heavily pretreated patients with relapsed or refractory myeloma at the 2026 ASCO Annual Meeting.